Drug
Giredestrant clinical trials
Also written GDC-9545 and RO7197597.
- studies test it
- 21
- open now
- 5
- in phase 3
- 7
- first study started
- 2018
Keep track of what changes. Save the giredestrant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
21 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 9
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 4
Hoffmann-La Roche (10) · Genentech, Inc. (7) · MedSIR (2) · ETOP IBCSG Partners Foundation (1) · Alliance Foundation Trials, LLC. (1)
Often tested with
Tested in the same studies.
Abemaciclib (4) · Inavolisib (4) · Letrozole (4) · Ipatasertib (3) · Atezolizumab (3) · Bevacizumab (3) · Ado-Trastuzumab Emtansine (2) · Paclitaxel (2)
Studies
Open first, then newest update. How each study uses giredestrant is read from its arms, and is right about nine times in ten.
Testing it · 21
- A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)RecruitingPhase 3Genentech, Inc.NCT07541079Written as Giredestrant
- A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During TreatmentNot yet recruitingPhase 3Hoffmann-La RocheNCT07827573Written as Giredestrant
- A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast CancerNot yet recruitingPhase 1Genentech, Inc.NCT07867262Written as Giredestrant
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Giredestrant
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352Written as Giredestrant
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT04961996Written as Giredestrant
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT05296798Written as Giredestrant
- A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruitingPhase 2MedSIRNCT05708235Written as Giredestrant
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT06065748Written as Giredestrant
- A Study of Giredestrant in Participants With Grade 1 Endometrial CancerCompletedPhase 2Hoffmann-La RocheNCT05634499Written as Giredestrant
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)Active, not recruitingPhase 2Hoffmann-La RocheNCT04576455Written as Giredestrant
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342Written as Giredestrant
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerTerminatedPhase 1Genentech, Inc.NCT07214662Written as Giredestrant
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT04546009Written as Giredestrant
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340Written as Giredestrant
- Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%CompletedPhase 2MedSIRNCT05659563Written as Giredestrant
- A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerCompletedPhase 2ETOP IBCSG Partners FoundationNCT05896566Written as Giredestrant
- A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast CancerCompletedPhase 1Genentech, Inc.NCT03916744Written as Giredestrant
- Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing PotentialCompletedPhase 1Genentech, Inc.NCT04680273Written as [14C]-GDC-9545
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)CompletedPhase 2Hoffmann-La RocheNCT04436744Written as Giredestrant
See all 21 studies that test giredestrant →
Given in every arm · 6 — giredestrant is usual care beside what is tested
- A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast CancerNot yet recruitingPhase 3PfizerNCT07890597Written as giredestrant
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingPhase 1/2PfizerNCT04557449Written as Giredestrant
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Giredestrant
- A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerRecruitingPhase 1/2Genentech, Inc.NCT07100106Written as Giredestrant
- A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07054190Written as Giredestrant
- A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerActive, not recruitingPhase 1Genentech, Inc.NCT03332797Written as GDC-9545
Codes
What other systems call giredestrant · ClinicalTrials.gg INT001743
- MeSH (NLM) C000720132giredestrantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 28P3DU6DB3GIREDESTRANTConfirmed FDA, NLM
- NCI Thesaurus C147030GiredestrantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720132 | giredestrant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 28P3DU6DB3 | GIREDESTRANT | Confirmed FDA, NLM |
| NCI Thesaurus | C147030 | Giredestrant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.